Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBmix
- Development stage
- Preclinical
- Lead developer
- Advanced Analytical Technologies
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
LBmix is an experimental probiotic combination consisting of two specific lactobacilli strains: *Lactobacillus crispatus* LMG P-23257 and *Lactobacillus rhamnosus* ATCC 53103. Developed for the treatment of autoimmune conditions, particularly Myasthenia Gravis, LBmix functions by modulating the gut microbiota and the host's immune response. Its mechanism of action involves interacting with the Gut-Associated Lymphoid Tissue (GALT), specifically dendritic cells and T cells within Peyer's Patches. This interaction is mediated by Toll-like receptor 2 (TLR2) recognition of bacterial lipoteichoic acid, which subsequently upregulates immunoregulatory markers such as Transforming Growth Factor-beta (TGFβ) and FoxP3. In preclinical models of Experimental Autoimmune Myasthenia Gravis (EAMG), LBmix has been shown to attenuate disease symptoms and reduce serum levels of anti-acetylcholine receptor (AChR) antibodies, although it was found to be less potent than bifidobacteria-based mixtures in therapeutic settings.
- Other names
- Lactobacilli mixLactobacillus mix
02
Targets
TLR2 (Toll-like Receptor 2)TGFB (GARP–latent transforming growth factor beta 1 complex)FOXP3 (Forkhead box protein P3)
Beyond the preview
Go deeper on LBmix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBmix.